Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01516437
Other study ID # 116021
Secondary ID
Status Completed
Phase N/A
First received January 19, 2012
Last updated January 15, 2015
Start date February 2012
Est. completion date December 2012

Study information

Verified date February 2013
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority Belgium: Federal Agency for Medicines and Health Products, FAMHP
Study type Interventional

Clinical Trial Summary

The present study aims to assess the natural immunity to specific microbial antigens in healthy subjects and in subjects with stable COPD aged between 45-75 years.


Recruitment information / eligibility

Status Completed
Enrollment 73
Est. completion date December 2012
Est. primary completion date June 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 45 Years to 75 Years
Eligibility Inclusion Criteria:

Healthy subjects (smokers and non-smokers)

- Subjects who the investigator believes can and will comply with the requirements of the protocol.

- A male or female between, and including 45 and 75 years of age at the time of consent.

- Written informed consent obtained from the subject.

- Baseline post-bronchodilator Forced Expiratory Volume of air in one second (FEV1) > 85% of predicted normal values and baseline post-bronchodilator FEV1/Forced expiratory Vital Capacity (FVC) > 70% of predicted normal values.

- Free of obvious health problems as established by medical history and clinical examination before entering into the study.

- Non-smokers: subjects who never smoked OR

- Smokers: current smoker having a smoking history = 10 pack-years.

COPD subjects (frequent and non-frequent exacerbators)

- Subjects who the investigator believes can and will comply with the requirements of the protocol.

- A male or female between, and including 45 and 75 years of age at the time of consent.

- Written informed consent obtained from the subject.

- Baseline post-bronchodilator FEV1 < 80% and >30% of predicted normal values and baseline post-bronchodilator FEV1/FVC < 70% of predicted normal values.

- Current or former smoker having a smoking history of = 10 pack-years.

- Documented history of = one exacerbation within 365 days prior to the screening visit that required treatment with systemic corticosteroids or resulted in hospitalization.

Exclusion Criteria:

Healthy subjects (smokers and non-smokers)

- Use of any investigational or non-registered product within 30 days prior to Screening Visit or planned use during the study.

- Concurrently participating in another clinical study in which the subject has been or will be exposed to an investigational or a non-investigational product.

- Any known clinically significant anaemia or any other condition as per medical records that would preclude the drawing of blood as described in the protocol.

- Receipt of any vaccine within 30 days preceding blood sampling.

- Previous vaccination with any NTHi vaccine.

- Chronic administration of immunosuppressants or other immune-modifying drugs within 180 days prior to screening visit. Topical steroids are allowed.

- Any confirmed or suspected immunosuppressive or immunodeficient condition including human immunodeficiency virus (HIV) infection, based on medical history and physical examination.

- Serious chronic disease including any medically significant chronic pulmonary, cardiovascular, renal, neurological, psychiatric or metabolic disorder, as determined by medical history and physical examination.

- Any known respiratory disorders.

- Acute disease and/or fever at the time of the Screening Visit or Visit 1, as applicable

- Receipt of immunoglobulins and/or any blood products within 90 days prior to Screening Visit.

- Receipt of interferon within 90 days prior to Screening Visit.

- History of malignancy.

- Subjects with a history of, or current, alcohol or substance abuse.

- Known history of immune-mediated disorder.

- Recent use of antibiotics or antiviral drug within 30 days prior to Screening Visit.

- Pregnant female.

- Other conditions that the investigator judges may interfere with study findings.

COPD subjects (frequent and non-frequent exacerbators)

- Use of any investigational or non-registered product within 30 days prior to Screening Visit or planned use during the study. Use of investigational inhaled long acting muscarinic antagonists (LAMA), inhaled long acting beta agonists (LABA) or inhaled corticosteroids is allowed.

- Concurrently participating in another clinical study in which the subject has been or will be exposed to an investigational or a non-investigational product. Subjects participating in clinical studies with investigational inhaled LAMA and/or LABA and/or inhaled corticosteroids can be enrolled.

- Any known clinically significant anaemia or any other condition as per medical records that would preclude the drawing of blood as described in the protocol.

- Receipt of any vaccine within 30 days preceding blood sampling.

- Previous vaccination with any NTHi vaccine.

- Any confirmed or suspected immunosuppressive or immunodeficient condition including human immunodeficiency virus (HIV) infection, based on medical history and physical examination.

- Serious, uncontrolled disease likely to interfere with the study findings.

- Acute disease and/or fever at the time of the Screening Visit or Visit 1, as applicable

- Receipt of immunoglobulins and/or any blood products within 90 days prior to Screening Visit.

- Receipt of interferon within 90 days prior to Screening Visit.

- History of malignancy.

- Subjects with a history of, or current, alcohol or substance abuse.

- Known history of immune-mediated disease other than COPD.

- Recent use of antibiotics or antiviral drug within 30 days prior to Screening Visit.

- Subject who experienced COPD exacerbation which required antibiotic, systemic corticosteroid or hospitalisation and which did not resolve at least one month prior to Screening Visit and at least 30 days following the last dose of oral corticosteroids.

- Chronic administration of immunosuppressants or other immune-modifying drugs within 180 days preceding screening visit.

- Subjects with very severe COPD, GOLD stage IV.

- Primary diagnosis of asthma.

- Other respiratory disorders such as sarcoidosis, tuberculosis, lung cancer, lung fibrosis, cystic fibrosis.

- A known diagnosis of a-1 antitrypsin deficiency as underlying cause of COPD.

- History of lung surgery.

- Pregnant female.

- Other conditions that the investigator judges may interfere with study findings.

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Procedure:
Blood collection
Blood collection at Day 0 (all subjects) and at Month 6 (COPD subjects) for the analysis of serology, cell-mediated immune response.
Swab collection
Nasopharyngeal and oropharyngeal swabs collection at Day 0 (All subjects) and at exacerbation visits (COPD subjects).
Sputum collection
Sputum collection at Day 0 and at exacerbation visits (COPD subjects)

Locations

Country Name City State
Belgium GSK Investigational Site Brussels
Belgium GSK Investigational Site Gent
Belgium GSK Investigational Site Liège

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Humoral immunity against specific microbial antigens At Day 0 No
Primary Humoral immunity against specific microbial antigens At Month 6 No
Secondary Cell-mediated immune responses against specific microbial antigens At Day 0 No
Secondary Occurrence of specific bacterial pathogens in sputum At Day 0 and at exacerbation visits (Month 1 to Month 6) No
Secondary Occurrence of specific bacterial pathogens in nasopharyngeal and oropharyngeal swabs At Day 0 and at exacerbation visits (Month 1 to Month 6) No
See also
  Status Clinical Trial Phase
Completed NCT01443845 - Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS) Phase 4
Withdrawn NCT00844935 - Electrocardiographic Autonomic Function Measures in Mechanically Ventilated Patients N/A
Completed NCT01395849 - Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol) N/A
Completed NCT03557645 - Ventilator Hyperinflation and Hemodynamics N/A
Completed NCT03281876 - A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response. Phase 2
Completed NCT01395862 - Special Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol) N/A
Completed NCT01476046 - Safety Study of GSK1995057 Given as Single and Repeat Intravenous Doses in Healthy Subjects. Phase 1
Completed NCT01587807 - A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Inhaled GSK1995057 Phase 1
Completed NCT00835003 - Timing of Planned Caesarean Section and Morbidity of the Newborn N/A
Completed NCT03443427 - A Study to Test if a Third Dose of the Vaccine is Safe in Current and Former Smokers Aged 40 to 80 Years Old and to Gather Information on the Immune Response Following the Third Dose of the Vaccine Phase 2
Completed NCT01360398 - Infectious Pathogens in Acute Respiratory Illness in Adults and Elderly N/A
Completed NCT03201211 - A Long Term Follow-up Study up to 4 Years After Study Vaccination to Assess Immunogenicity and Safety of the Investigational Vaccine in Adults Phase 1
Completed NCT02075541 - A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithkline (GSK) Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients With Persistent Airflow Obstruction. Phase 2
Completed NCT00455767 - Safety and Efficacy Study of Depelestat in Acute Respiratory Distress Syndrome (ARDS) Patients Phase 2
Withdrawn NCT01505556 - Proprioceptive Postural Control and Diaphragm Paresis
Completed NCT01505582 - Inspiratory Muscle Training and Low Back Pain N/A
Completed NCT02322671 - Relative Bioavailability Study of Two Montelukast Sodium (GW483100) 5 Milligrams (mg) Chewable Tablets and One Reference Montelukast Sodium 5 mg Chewable Tablet in Healthy Adult Subjects Phase 1
Completed NCT01818024 - A Study to Investigate the Safety Tolerability Pharmacokinetics, and Pharmacodynamics of Inhaled and Intravenous GSK2862277 in Healthy Volunteers Phase 1
Recruiting NCT02316379 - Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration Phase 1/Phase 2
Recruiting NCT02272049 - Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults Phase 1/Phase 2